Wyeth sees new competition for Effexor anti-depressant drug
The dinger: the new drug, which will be sold as a generic, will have the same active ingridient at Wyeth's $3.7 billion-a-year Effexor drug. Think that's a threat? Sure -- big-time.
The difference here that makes this potential new anti-depressant such a big deal is because it comes in an extended-release tablet as opposed to a capsule (which is under Wyeth patent protection until 2010). Nothing like finding a loophole for new drug sales, huh?







.jpg)










